Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology

Brendan Frett, Francesca Carlomagno, Maria Luisa Moccia, Annalisa Brescia, Giorgia Federico, Valentina Defalco, Brittany Admire, Zhongzhu Chen, Wenqing Qi, Massimo Santoro, Hong Yu Li

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is associated with several cancers. A fragment-based chemical screen led to the identification of a novel RET inhibitor, Pz-1. Modeling and kinetic analysis identified Pz-1 as a typeII tyrosine kinase inhibitor that is able to bind the "DFG-out" conformation of the kinase. Importantly, from a single-agent polypharmacology standpoint, Pz-1 was shown to be active on VEGFR2, which can block the blood supply required for RET-stimulated growth. In cell-based assays, 1.0nM of Pz-1 strongly inhibited phosphorylation of all tested RET oncoproteins. At 1.0mg kg-1 day-1 per os, Pz-1 abrogated the formation of tumors induced by RET-mutant fibroblasts and blocked the phosphorylation of both RET and VEGFR2 in tumor tissue. Pz-1 featured no detectable toxicity at concentrations of up to 100.0mg kg-1, which indicates a large therapeutic window. This study validates the effectiveness and usefulness of a medicinal chemistry/polypharmacology approach to obtain an inhibitor capable of targeting multiple oncogenic pathways. Dual inhibition: A kinase-directed fragment-based screen identified a novel active pharmacophore for the RET tyrosine kinase (RET=rearranged during transfection). In a medicinal chemistry/polypharmacology approach, Pz-1 was found to be a dual pan-RET/VEGFR2 inhibitor and able to simultaneously treat the parenchyma (RET) and stroma (VEGFR2) of RET-driven tumors in cell and xenograft models.

Original languageEnglish (US)
Pages (from-to)8717-8721
Number of pages5
JournalAngewandte Chemie - International Edition
Volume54
Issue number30
DOIs
StatePublished - Jul 20 2015

Fingerprint

Protein-Tyrosine Kinases
Tumors
Phosphorylation
Phosphotransferases
Oncogene Proteins
Fibroblasts
Heterografts
Toxicity
Conformations
Assays
Blood
Tissue
Kinetics
Pharmaceutical Chemistry

Keywords

  • inhibitors
  • kinases
  • medicinal chemistry
  • polypharmacology

ASJC Scopus subject areas

  • Chemistry(all)
  • Catalysis

Cite this

Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. / Frett, Brendan; Carlomagno, Francesca; Moccia, Maria Luisa; Brescia, Annalisa; Federico, Giorgia; Defalco, Valentina; Admire, Brittany; Chen, Zhongzhu; Qi, Wenqing; Santoro, Massimo; Li, Hong Yu.

In: Angewandte Chemie - International Edition, Vol. 54, No. 30, 20.07.2015, p. 8717-8721.

Research output: Contribution to journalArticle

Frett, B, Carlomagno, F, Moccia, ML, Brescia, A, Federico, G, Defalco, V, Admire, B, Chen, Z, Qi, W, Santoro, M & Li, HY 2015, 'Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology', Angewandte Chemie - International Edition, vol. 54, no. 30, pp. 8717-8721. https://doi.org/10.1002/anie.201501104
Frett, Brendan ; Carlomagno, Francesca ; Moccia, Maria Luisa ; Brescia, Annalisa ; Federico, Giorgia ; Defalco, Valentina ; Admire, Brittany ; Chen, Zhongzhu ; Qi, Wenqing ; Santoro, Massimo ; Li, Hong Yu. / Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. In: Angewandte Chemie - International Edition. 2015 ; Vol. 54, No. 30. pp. 8717-8721.
@article{85ed751ecd9a411f93d00505f76689ed,
title = "Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology",
abstract = "Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is associated with several cancers. A fragment-based chemical screen led to the identification of a novel RET inhibitor, Pz-1. Modeling and kinetic analysis identified Pz-1 as a typeII tyrosine kinase inhibitor that is able to bind the {"}DFG-out{"} conformation of the kinase. Importantly, from a single-agent polypharmacology standpoint, Pz-1 was shown to be active on VEGFR2, which can block the blood supply required for RET-stimulated growth. In cell-based assays, 1.0nM of Pz-1 strongly inhibited phosphorylation of all tested RET oncoproteins. At 1.0mg kg-1 day-1 per os, Pz-1 abrogated the formation of tumors induced by RET-mutant fibroblasts and blocked the phosphorylation of both RET and VEGFR2 in tumor tissue. Pz-1 featured no detectable toxicity at concentrations of up to 100.0mg kg-1, which indicates a large therapeutic window. This study validates the effectiveness and usefulness of a medicinal chemistry/polypharmacology approach to obtain an inhibitor capable of targeting multiple oncogenic pathways. Dual inhibition: A kinase-directed fragment-based screen identified a novel active pharmacophore for the RET tyrosine kinase (RET=rearranged during transfection). In a medicinal chemistry/polypharmacology approach, Pz-1 was found to be a dual pan-RET/VEGFR2 inhibitor and able to simultaneously treat the parenchyma (RET) and stroma (VEGFR2) of RET-driven tumors in cell and xenograft models.",
keywords = "inhibitors, kinases, medicinal chemistry, polypharmacology",
author = "Brendan Frett and Francesca Carlomagno and Moccia, {Maria Luisa} and Annalisa Brescia and Giorgia Federico and Valentina Defalco and Brittany Admire and Zhongzhu Chen and Wenqing Qi and Massimo Santoro and Li, {Hong Yu}",
year = "2015",
month = "7",
day = "20",
doi = "10.1002/anie.201501104",
language = "English (US)",
volume = "54",
pages = "8717--8721",
journal = "Angewandte Chemie - International Edition",
issn = "1433-7851",
publisher = "John Wiley and Sons Ltd",
number = "30",

}

TY - JOUR

T1 - Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology

AU - Frett, Brendan

AU - Carlomagno, Francesca

AU - Moccia, Maria Luisa

AU - Brescia, Annalisa

AU - Federico, Giorgia

AU - Defalco, Valentina

AU - Admire, Brittany

AU - Chen, Zhongzhu

AU - Qi, Wenqing

AU - Santoro, Massimo

AU - Li, Hong Yu

PY - 2015/7/20

Y1 - 2015/7/20

N2 - Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is associated with several cancers. A fragment-based chemical screen led to the identification of a novel RET inhibitor, Pz-1. Modeling and kinetic analysis identified Pz-1 as a typeII tyrosine kinase inhibitor that is able to bind the "DFG-out" conformation of the kinase. Importantly, from a single-agent polypharmacology standpoint, Pz-1 was shown to be active on VEGFR2, which can block the blood supply required for RET-stimulated growth. In cell-based assays, 1.0nM of Pz-1 strongly inhibited phosphorylation of all tested RET oncoproteins. At 1.0mg kg-1 day-1 per os, Pz-1 abrogated the formation of tumors induced by RET-mutant fibroblasts and blocked the phosphorylation of both RET and VEGFR2 in tumor tissue. Pz-1 featured no detectable toxicity at concentrations of up to 100.0mg kg-1, which indicates a large therapeutic window. This study validates the effectiveness and usefulness of a medicinal chemistry/polypharmacology approach to obtain an inhibitor capable of targeting multiple oncogenic pathways. Dual inhibition: A kinase-directed fragment-based screen identified a novel active pharmacophore for the RET tyrosine kinase (RET=rearranged during transfection). In a medicinal chemistry/polypharmacology approach, Pz-1 was found to be a dual pan-RET/VEGFR2 inhibitor and able to simultaneously treat the parenchyma (RET) and stroma (VEGFR2) of RET-driven tumors in cell and xenograft models.

AB - Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is associated with several cancers. A fragment-based chemical screen led to the identification of a novel RET inhibitor, Pz-1. Modeling and kinetic analysis identified Pz-1 as a typeII tyrosine kinase inhibitor that is able to bind the "DFG-out" conformation of the kinase. Importantly, from a single-agent polypharmacology standpoint, Pz-1 was shown to be active on VEGFR2, which can block the blood supply required for RET-stimulated growth. In cell-based assays, 1.0nM of Pz-1 strongly inhibited phosphorylation of all tested RET oncoproteins. At 1.0mg kg-1 day-1 per os, Pz-1 abrogated the formation of tumors induced by RET-mutant fibroblasts and blocked the phosphorylation of both RET and VEGFR2 in tumor tissue. Pz-1 featured no detectable toxicity at concentrations of up to 100.0mg kg-1, which indicates a large therapeutic window. This study validates the effectiveness and usefulness of a medicinal chemistry/polypharmacology approach to obtain an inhibitor capable of targeting multiple oncogenic pathways. Dual inhibition: A kinase-directed fragment-based screen identified a novel active pharmacophore for the RET tyrosine kinase (RET=rearranged during transfection). In a medicinal chemistry/polypharmacology approach, Pz-1 was found to be a dual pan-RET/VEGFR2 inhibitor and able to simultaneously treat the parenchyma (RET) and stroma (VEGFR2) of RET-driven tumors in cell and xenograft models.

KW - inhibitors

KW - kinases

KW - medicinal chemistry

KW - polypharmacology

UR - http://www.scopus.com/inward/record.url?scp=84947869287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947869287&partnerID=8YFLogxK

U2 - 10.1002/anie.201501104

DO - 10.1002/anie.201501104

M3 - Article

VL - 54

SP - 8717

EP - 8721

JO - Angewandte Chemie - International Edition

JF - Angewandte Chemie - International Edition

SN - 1433-7851

IS - 30

ER -